Psychedelic Research Recap November 2025
Psychedelic research in November examined microdosing outcomes, brain criticality and plasticity mechanisms, and clinical applications for depression, PTSD, and end-of-life care.
Psychedelic research in November examined microdosing outcomes, brain criticality and plasticity mechanisms, and clinical applications for depression, PTSD, and end-of-life care.
Psychedelic research in October investigated brain plasticity, set and setting, and microdosing.
Psychedelic research in September focussed on MDMA, psilocybin, LSD, and ayahuasca clinical trials across diverse indications.
Psychedelic research in August 2025 (162 studies, 10 added to the database) looked at psilocybin for PTSD, economic evaluations of psychedelic therapies, the brain mechanisms of tabernanthalog, and much more.
Psychedelic research in July 2025 (181 studies, 18 added to the database) looked at the receptors psychedelics influence, naturalistic psychedelic use, and much more.
Psychedelic research in June 2025 (146 studies, 18 added to the database) looked at long-term effects of psilocybin therapy for depression, ‘meaning of life’ after psychedelic use, unblinding effects, and more.
Psychedelic research in May 2025 shows ketamine saves healthcare costs, esketamine remains safe long-term, and these therapies work differently than expected.
In April 2025, psychedelic researchers published 172 studies and we’ve added 17 new papers to the database. This month featured ketamine for smoking cessation, HPPD after psychedelic use, effects of DMT on TRD, and much more.
In March 2025, psychedelic researchers published 138 studies and we’ve added 11 new papers to the database. This month featured psilocybin for alcoholism (AUD), microdosing for ADHD, long-term follow-up, and several investigations into how psychedelics work.
In February 2025, psychedelic research continued with 11 new studies and 193 linked studies. This month featured investigations into therapeutic applications for alcohol use disorder, pharmacological interactions, brain connectivity changes, visual perception effects, and the emotional dimensions of psychedelic experiences.